Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021,...
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
September 29, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Non-dilutive committed capital extends cash runway into at least 2024 Facility strengthens balance sheet through anticipated commercial launches of Axsome’s two lead CNS product candidates NEW YORK,...
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
September 21, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021 Extensive patient safety database, previously obtained...
Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 08, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
August 28, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 10, 2020 07:05 ET
|
Axsome Therapeutics, Inc.
Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020 Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3...
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
August 05, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 30, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics to Present at Upcoming Investor Conferences
June 04, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...